Cytochrome P450 2D6 genotype variation and venlafaxine dosage

Mayo Clinic Proceedings

Volumn 82, Issue 9, 2007, Pages 1065-1068

  McAlpine, Donald E ^a   O'Kane, Dennis J ^a   Black, John L ^a   Mrazek, David A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; VENLAFAXINE;

ADOLESCENT; ADULT; ALLELE; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG RELEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTHYMIA; FEMALE; GENETIC VARIABILITY; HUMAN; MAJOR DEPRESSION; MALE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 34548399738     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/82.9.1065     Document Type: Article

References (14)

1. Alexanderson B, Evans DA, Sjöqvist F. Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br Med J. 1969;4(5686):764-768.
2. Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003;348(6):529-537.
3. Fukuda T, Yamamoto I, Nishida Y, et al. Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. Br J Clin Pharmacol. 1999;47(4):450-453.
4. Dalén P, Dahl ML, Bernal Ruiz MLB, Nordin J, Bertilsson L. 10-Hydroxylation of nortriptyline in white persons with 0,1,2,3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther. 1998;63(4):444-452.
5. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997;60(2):284-295.
6. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9(5):442-473.
7. Rau T, Wohlleben G, Wuttke H, et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants - a pilot study. Clin Pharmacol Ther. 2004;75(5):386-393.
8. Lessard E, Yessine MA, Hamelin BA, O'Hara G, LeBlanc J, Turgeon J. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics. 1999;9(4):435-443.
9. Fogelman SM, Schmider J, Venkatakrishnan K, et al. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology. 1999;20(5):480-490.
10. Eap CB, Lessard E, Baumann P, et al. Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. Pharmacogenetics. 2003;13(1):39-47.
11. Ereshefsky L, Dugan D. Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. Depress Anxiety. 2000;129(suppl 1):30-44.
12. Thase ME, Sloan DME. Venlafaxine. In: Schatzberg A, Nemeroff C, eds. Textbook of Psychopharmacology. 3rd ed. Washington, DC: American Psychiatric Publishing; 2004:349-360.
13. Mrazek DA. New tool: genotyping makes prescribing safer, more effective. Curr Psychiatry. 2004;3(9):11-23.
14. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet. 1989;45:889-904.